

SUGGESTED PROCEDURE

Item	Tetracaine 4.0% Lollipops	Formula Date	13 Nov 2024
API(s)	Tetracaine Hydrochloride	Procedure No.	P2711
Base	Nextol SF™	Revision	R4
Volume/Quantity	10 Lollipops	Compound Type	Anhydrous Lollipop

Rx	Weight (g)	Percent	Comment
Tetracaine HCl, USP	3.08g	4.0%	Melting point roughly 148°C
Nextol SF™	73.52g	95.5%	qs Approx density in finished candy state: 1.38-1.42 g/cm ³
SpecializedRx WS Natural Liquid Flavor Concentrate	0.4ml	0.5%	To taste
Total	77g	100%	

Average Nextol SF™ calibration placebo weight using SmartPops™ Lollipop molds is 7.70g per mold cavity.

To account for processing error considerations during preparation, it is suggested to measure an additional **10%** of the required quantities of ingredients.

Suggested Method of Preparation

1. Calculate the required quantity of each ingredient for the total amount to be prepared.
2. Accurately weigh and/or measure each ingredient. Account for batch size and density conversions, if required.
3. Melt the Nextol SF™ base at 145-150°C (hard crack stage). Do not overheat.
4. Remove from heat and allow to cool to 90°C.
5. Slowly add Tetracaine HCl powder to the base, making sure to prevent clumping and ensuring addition is wetted before adding additional powder while maintaining a good working temperature. Mix thoroughly.
6. Nextol SF™ is workable down to roughly 60°C before it will start to harden.
7. Pour the mixture in the molds or fill individual cavities with a large capacity glass pipette, quickly filling each cavity.
8. Set times will vary. Hard set should usually be between 6-8 hours.
9. Apply CR cap and label.
10. Suggested Quality assessments
 - a. Appearance and feel
 - b. Quantity
 - c. Label: auxiliary labels, storage, BUD, compounded medication, for external use only

Packaging: Tight, light-resistant container, SmartPops™

Estimated Beyond Use Date: 180 days per USP 795*

Labeling: Keep out of reach of children. Use only as directed. Protect from moisture and light.

Stability: Anhydrous formulation.

Note: Potency Range Recommendation: ≥90% and ≤110% of the theoretically calculated active(s).

*Beyond-Use Date should be based on the current USP General Chapter <795>. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounding and contamination of the preparation by the compounding. No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist. Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounding may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

WARNING! Precautions should be taken when handling APIs as they can be absorbed through the skin, mucus membranes and lungs if inhaled. Always wear protective lab apparel, gloves, eye protection, respirator / work under a safety cabinet.

Disclaimer: SpecializedRx makes no warranties or claims to the safety, accuracy, or efficacy of the above information, expressed or implied given the variations in use, materials, and formulations. SpecializedRx accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold SpecializedRx and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein. This is a copyrighted formula that may not otherwise be distributed, copied or disclosed without SRx's written permission. This formula is subject to SRx intellectual property rights.